This week, dietary supplements are OTCs in Action, with Nicholas Hall & Company’s OTC.NewDirections e-bulletin last week reporting on promising scientific studies around the world. We also report on BLIS Technologies / Stratum’s success with probiotic health claims in Canada. From OTC.NewDirections:
- Resveratrol is more effective in smaller doses at preventing bowel cancer in mice than high doses, according to University of Leicester and Lawrence Livermore National Laboratory scientists. Dietary doses (equivalent to one large glass of red wine) or doses 200x higher, were fed to bowel cancer-prone mice with a standard or high-fat diet. The lower dose produced a 50% reduction in tumor size, vs a 25% reduction with the higher dose in mice fed a high-fat diet. (Science Translational Medicine, July 29, 2015)
- Probiotic supplementation may prevent infantile eczema, according to the Task Force on Probiotics of the Italian Society of Neonatology. A meta-analysis of 17 studies, involving 4,755 children, showed infants treated with probiotics had a significantly lower risk (22%) for eczema vs controls; infants treated with a combination of probiotics had a 46% reduced risk for eczema. (Allergy, July 21, 2015)
- Researchers from Ljungby Public Dental Clinic, University of Copenhagen and Halland Hospital studied a group of 215 people, aged 60-102 years, who were given a lozenge containing two strains of Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) or placebo in the morning and evening for 12 weeks. Saliva and plaque samples showed that there was a statistically significant reduction in high Candida counts for both saliva and plaque in the probiotic group vs placebo. (Journal of Dental Research, July 22, 2015)
Investment in similar research by BLIS Technologies and Stratum Nutrition has led to the recent approval from Health Canada to make claims for BLIS K12 probiotics, including:
- “promotes oral health (through the re-colonisation of the oral cavity)”
- is an “oral probiotic for re-colonisation of the oral cavity after antibiotic treatment”
- “following oral antimicrobial rinsing, Streptococcus salivarius K12 supplementation helps reduce volatile sulfur compound levels (halitosis)”
- “can help reduce the incidence of Streptococcal pharyngitis / tonsillitis (sore throats caused by pathogenic variants belonging to the Streptococcus genus)”.
BLIS and partner Stratum’s focus on regulatory approvals is a means of opening up markets. “As arduous as the process is, each successful regulatory approval prepares the ground for the sales and marketing effort that follows,” commented Barry Richardson, CEO of BLIS. Last year, Prairie Naturals / Stratum’s CulturedCare Probiotic Gum using BLIS K12 was granted a product licence by Health Canada.